Stefan Fröhling, DKFZ/NCT, Germany

Stefan Fröhling has been Head of the Division of Translational Medical Oncology at the German Cancer Research Center (DKFZ) since 2019 and Managing Director of the National Center for Tumor Diseases (NCT) Heidelberg since 2020. His work at the interface of applied cancer research and clinical care centers on strategies for multidimensional tumor characterization as a basis for academic clinical trials, investigating the efficacy of novel, individualized cancer therapies. In addition to his activities in the field of cross-entity precision oncology, Stefan Fröhling focuses on translating insights into the biology of bone and soft-tissue sarcomas and myeloid malignancies into novel diagnostic and therapeutic strategies. Locally, he directs the NCT Molecular Precision Oncology Program; on a national level, he coordinates the Research Platform “Cancer Genome Analysis” of the German Cancer Consortium (DKTK) and the DKFZ/NCT/DKTK MASTER (Molecularly Aided Stratification for Tumor Eradication Research) Program, activities that have paved the way for the widespread implementation of genetically guided precision oncology and its transition into standard care in Germany. Internationally, he is a member of the Board of Directors of Cancer Core Europe (CCE) and has long been active in the European Hematology Association (EHA), including a four-year term as an elected board member. In addition to his scientific and clinical activities, which are characterized by a strong commitment to the involvement of patients as research partners, Stefan Fröhling has a particular interest in the education and training of physician-scientists and medical scientists.

Read more